Ptprg and BCR/ABL1 Expression In CML Patients At Diagnosis and Upon TKI Treatment: Preliminary Results

被引：0
|
作者：
Monne, Maria
Piras, Giovanna
Vezzalini, Marzia
Bras, Antonella
Murineddu, Marco
Yassin, Mohamed A.
Al-Dewik, Nader I.
Latte, Giancarlo
Sorio, Claudio
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.5163.5163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5163
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Deletions of the Normal ABL1 at the Non-Translocated Chromosome 9 in CML Associated with TKI Resistance
    Virgili, Anna
    Brazma, Diana
    Grace, Colin
    Nacheva, Elisabeth P.
    BLOOD, 2009, 114 (22) : 1260 - 1260
  • [22] RIBOZYME AND ANTISENSE DNA REGULATION OF BCR/ABL EXPRESSION IN CML PATIENTS
    KEARNEY, PP
    WRIGHT, LA
    MILLIKEN, S
    BIGGS, JC
    WILSON, SB
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 233 - 233
  • [23] Kinetics of BCR-ABL Mutant Clones Determines Resistance in CML on Second Generation TKI Treatment
    Gruber, Franz X.
    Ernst, Thomas
    Maier, Jaqueline
    Mueller, Martin C.
    Mikkola, Ingvild
    Porkka, Kimmo
    Niederwieser, Dietger
    Hochhaus, Andreas
    Lange, Thoralf
    BLOOD, 2008, 112 (11) : 741 - 741
  • [24] Infections and vaccination in patients with BCR::ABL1 negative myeloproliferative neoplasms
    Haberbosch, S. M.
    Mertin, F.
    Hochhaus, A.
    Heidel, F.
    Hilgendorf, I
    Crodel, C. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 108 - 108
  • [25] Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
    Haddad, Fadi G.
    Kantarjian, Hagop
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (01):
  • [26] Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
    Valent, Peter
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (10) : 918 - 931
  • [27] Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study
    Murbach, Bruna
    Duarte, Gislaine
    Palma, Leonardo Carvalho
    Miranda, Eliana
    Duffles, Guilherme
    Furlin, Graziele Pavan
    Toni, Isabella
    De Souza, Carmino
    Binelli, Larissa
    Bassan, Vitor Leonardo
    de Castro, Fabiola Attie
    Figueiredo-Pontes, Lorena Lobo de
    Pagnano, Katia Borgia Barbosa
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] The importance of Bcr-Abl-dependent EpCAM Expression for the Treatment of Treatment Resistance of CML
    Towhidi, T.
    Zhuang, R.
    Jucker, M.
    Boddu, V. K.
    Gires, O.
    Busch, H.
    Illert, L.
    Duyster, J.
    Gemoll, T.
    Gieseler, F.
    Von Bubnoff, N.
    Gorantla, S. Prasad
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 121 - 121
  • [29] Detection of the BCR ABL1 Translocation in Patients with Chronic Myelogenous Leukemia (CML) by DNA based Looped Ligation Assay (LOLA)
    Harada, S.
    Silzle, E.
    Gocke, C. D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (06): : 868 - 868
  • [30] The significance of BCR-ABL dependent EpCAM expression for treatment resistance in CML
    Towhidi, Tara
    Zhuang, Ruimeng
    Juecker, Manfred
    Boddu, Vijay Kumar
    Gires, Oliver
    Busch, Hauke
    Illert, Lena
    Duyster, Justus
    Gemoll, Timo
    Gieseler, Frank
    von Bubnoff, Nikolas
    Gorantla, Sivahari Prasad
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 144 - 144
12345